Compare HNRG & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNRG | NVCT |
|---|---|---|
| Founded | 1949 | 2020 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Coal Mining | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 763.0M | 721.2M |
| IPO Year | 1995 | 2021 |
| Metric | HNRG | NVCT |
|---|---|---|
| Price | $17.53 | $26.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $25.38 | $10.00 |
| AVG Volume (30 Days) | ★ 731.7K | 201.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 116.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $469,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.09 | N/A |
| 52 Week Low | $14.68 | $5.55 |
| 52 Week High | $24.70 | $27.93 |
| Indicator | HNRG | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 90.33 |
| Support Level | $17.26 | $6.74 |
| Resistance Level | $20.40 | N/A |
| Average True Range (ATR) | 1.02 | 2.09 |
| MACD | 0.05 | 1.85 |
| Stochastic Oscillator | 43.81 | 93.56 |
Hallador Energy Co is a vertically integrated, independent power producer (IPP) and fuel company with operations in Indiana. The Company operates across multiple stages of the energy value chain, from accredited capacity and energy to coal. The Company's electric operations are located within the Midcontinent Independent System Operator's (MISO) footprint. The company's business is organized based on the services and products it provide in two segments: (i) Electric Operations and (ii) Coal Operations.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.